On Monday, the parliamentary standing committee on health and family welfare submitted a report to the Rajya Sabha recommending that cancer should be declared as a ‘notified disease’ citing many unreported cancer deaths in India. The committee also noted that this hinders data collection due to the ambiguity of the actual cause of death and called for a CoWin-like portal for registration.&nbsp;

The committee made these recommendations in the 139th report on “Cancer Care Plan and Management: Prevention, Diagnosis, Research &amp; Affordability of Cancer Treatment” submitted to the Chairman of the upper house of Parliament. “The Committee notes that Cancer is still not classified as a notifiable disease which results in underreporting of cancer deaths…It has been brought to the notice of the Committee that many times death is simply recorded as a cardio-respiratory failure without mentioning the actual cause of death,” states the report.&nbsp;

A ‘notifiable disease’ is any disease that a citizen needs to report to the public health authorities, which is mandated by law. The collation of this information allows the authorities to monitor the disease and issue early warnings in case of a possible outbreak. Therefore, the committee has called for cancer to be a notified disease which would mandatorily require cancer deaths to be reported to the government machinery. &nbsp;

The panel headed by MP Ram Gopal Yadav also called for a CoWin-like portal for registration, which would aid real-time data collection, and counselling, while also offering supportive resources for cancer care with interactive tools. The report added, “The portal can also be equipped to aid those affected by cancer by guiding them through the treatment and management journey”.&nbsp;

Meanwhile, they have also expressed displeasure over the current mechanism in place which is the National Cancer Registry Programme (NCRP). The NCRP has been working since 1982 through two other registries, Population Based Cancer Registry (PBCR) and Hospital Based Cancer Registry (HBCR). Notably, only 10% of the Indian population is covered by PBCRs. The committee strongly believes that there is an urgent need for rural-based PBCRs “to get realistic information about the incidence and type of cancers across the country.”&nbsp;

The committee also called upon the National Centre for Disease Informatics and Research (ICMR) to take requisite action and set up a population-based cancer registry in rural areas of these states – Uttar Pradesh, Madhya Pradesh, Andhra Pradesh, Rajasthan, Telangana, and Orissa. “Such requisite action is all the more necessary to collect data &amp; information not only for policy making on cancer treatment but also for uniform distribution of cancer care,” the report noted.&nbsp;

The Ministry must also expand the scope of PBCR and ensure conducting more rural-based PBCRs to get accurate information about the incidence and types of cancer across the country, said the committee. They also recommend that the Ministry link the Cancer Registry data with Ayushman Bharat/PMJY, mortality databases, and the Hospital Information System (HIS) which they believe would improve cancer registration, follow-up, and outcome data.&nbsp;

(With inputs from agencies)&nbsp; 
&nbsp;

On Monday, the parliamentary standing committee on health and family welfare submitted a report to the Rajya Sabha recommending that cancer should be declared as a ‘notified disease’ citing many unreported cancer deaths in India.

On Monday, the parliamentary standing committee on health and family welfare submitted a report to the Rajya Sabha recommending that cancer should be declared as a ‘notified disease’ citing many unreported cancer deaths in India. The committee also noted that this hinders data collection due to the ambiguity of the actual cause of death and called for a CoWin-like portal for registration. The committee made these recommendations in the 139th report on “Cancer Care Plan and Management: Prevention, Diagnosis, Research & Affordability of Cancer Treatment” submitted to the Chairman of the upper house of Parliament. “The Committee notes that Cancer is still not classified as a notifiable disease which results in underreporting of cancer deaths…It has been brought to the notice of the Committee that many times death is simply recorded as a cardio-respiratory failure without mentioning the actual cause of death,” states the report. A ‘notifiable disease’ is any disease that a citizen needs to report to the public health authorities, which is mandated by law. The collation of this information allows the authorities to monitor the disease and issue early warnings in case of a possible outbreak. Therefore, the committee has called for cancer to be a notified disease which would mandatorily require cancer deaths to be reported to the government machinery. The panel headed by MP Ram Gopal Yadav also called for a CoWin-like portal for registration, which would aid real-time data collection, and counselling, while also offering supportive resources for cancer care with interactive tools. The report added, “The portal can also be equipped to aid those affected by cancer by guiding them through the treatment and management journey”. Meanwhile, they have also expressed displeasure over the current mechanism in place which is the National Cancer Registry Programme (NCRP). The NCRP has been working since 1982 through two other registries, Population Based Cancer Registry (PBCR) and Hospital Based Cancer Registry (HBCR). Notably, only 10% of the Indian population is covered by PBCRs. The committee strongly believes that there is an urgent need for rural-based PBCRs “to get realistic information about the incidence and type of cancers across the country.” The committee also called upon the National Centre for Disease Informatics and Research (ICMR) to take requisite action and set up a population-based cancer registry in rural areas of these states – Uttar Pradesh, Madhya Pradesh, Andhra Pradesh, Rajasthan, Telangana, and Orissa. “Such requisite action is all the more necessary to collect data & information not only for policy making on cancer treatment but also for uniform distribution of cancer care,” the report noted. The Ministry must also expand the scope of PBCR and ensure conducting more rural-based PBCRs to get accurate information about the incidence and types of cancer across the country, said the committee. They also recommend that the Ministry link the Cancer Registry data with Ayushman Bharat/PMJY, mortality databases, and the Hospital Information System (HIS) which they believe would improve cancer registration, follow-up, and outcome data. (With inputs from agencies)

Cancer should be made a ‘notified disease’, recommends Parliamentary panel

Let's be honest, can we actually walk out a way to fitness? Walking is one of the most effective, affordable, and straightforward exercises.&nbsp;

A recent study claims that walking 10,000 steps a day lowers the risk of dementia, cancer, heart attack, and mortality.

The study was published in the journals JAMA Internal Medicine and JAMA Neurology.

The study used data from the UK biobank to correlate step counts from 78,500 UK&nbsp;adults aged between 40 and 79. However, individuals who were free of cardiovascular disease, cancer, or dementia were included in the final assessment.

<a href="https://www.wionews.com/science/study-reveals-this-blood-test-can-now-detect-if-you-have-cancer-without-any-symptoms-515311">Aldo read |&nbsp;Study reveals this blood test can now detect if you have cancer without any clear symptoms&nbsp;</a>

The study monitored 75,800 adults with wearable trackers, making it the largest study to objectively track step counts in relation to health outcomes.&nbsp;

Head researcher, Dr. Matthew Ahmadi, said, "The take-home message here is that for protective health benefits, people could not only ideally aim for 10,000 steps a day but also aim to walk faster," ANI reported.

However, for less active individuals, the study offers an option for them to maintain their health. Borja del Pozo, associate researcher, Cruz said that the research also shows that as few as 3,800 steps a day can cut the risk of dementia by 25 per cent.

<a href="https://www.wionews.com/science/study-reveals-meal-times-has-little-effect-on-weight-loss-514946">Also read |&nbsp;Study reveals timing of your largest meal has little effect on weight loss</a>

The study also claims that every 2,000 steps reduce the risk of premature death incrementally by 8 to 11 per cent nearly 10,000 steps a day.

Ahmadi said, "The size and scope of these studies using wrist-worn trackers make it the most robust evidence to date suggesting that 10,000 steps a day is the sweet spot for health benefits and walking faster is associated with additional benefits," ANI reported.&nbsp;

(With inputs from agencies)

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

Let's be honest, can we actually walk out a way to fitness? Walking is one of the most effective, affordable, and straightforward exercises. A recent study claims that walking 10,000 steps a day lowers the risk of dementia, cancer, heart attack, and mortality.

Let's be honest, can we actually walk out a way to fitness? Walking is one of the most effective, affordable, and straightforward exercises. A recent study claims that walking 10,000 steps a day lowers the risk of dementia, cancer, heart attack, and mortality. The study was published in the journals JAMA Internal Medicine and JAMA Neurology. The study used data from the UK biobank to correlate step counts from 78,500 UK adults aged between 40 and 79. However, individuals who were free of cardiovascular disease, cancer, or dementia were included in the final assessment. Aldo read | Study reveals this blood test can now detect if you have cancer without any clear symptoms The study monitored 75,800 adults with wearable trackers, making it the largest study to objectively track step counts in relation to health outcomes. Head researcher, Dr. Matthew Ahmadi, said, "The take-home message here is that for protective health benefits, people could not only ideally aim for 10,000 steps a day but also aim to walk faster," ANI reported. However, for less active individuals, the study offers an option for them to maintain their health. Borja del Pozo, associate researcher, Cruz said that the research also shows that as few as 3,800 steps a day can cut the risk of dementia by 25 per cent. Also read | Study reveals timing of your largest meal has little effect on weight loss The study also claims that every 2,000 steps reduce the risk of premature death incrementally by 8 to 11 per cent nearly 10,000 steps a day. Ahmadi said, "The size and scope of these studies using wrist-worn trackers make it the most robust evidence to date suggesting that 10,000 steps a day is the sweet spot for health benefits and walking faster is associated with additional benefits," ANI reported. (With inputs from agencies) WATCH WION LIVE HERE

Walking 10,000 steps per day reduces risk of dementia, cancer, and mortality: Study

Researchers have discovered a new treatment for advanced melanoma during the Phase 3 clinical trial. They claim that it is far more effective than the existing leading therapy for metastatic melanoma.

The scientists at the Netherlands Cancer Institute said that the new treatment uses a patient’s own immune cells to fight cancer, and added that its therapy is similar to another type of treatment that has proven to be highly effective for blood cancers, called CAR-T therapy.

Under CAR-T therapy, patients’ T-cells are harvested and modified in the lab into cancer fighters. These modified cells are then infused back into the patient.

Similarly in the melanoma trial, the researchers used an approach called TIL therapy, which involves harvesting a patient’s immune cells—tumour-infiltrating lymphocytes, which are taken from the tumour.

But instead of modifying these tumour cells in the lab like the CAR-T therapy, they’re simply amplified to produce billions of immune cells.

Those amplified immune cells are then injected back into the patient’s blood, where they work to kill the cancer.

Dr John Haanen, a medical oncologist at the Netherlands Cancer Institute, who led the new clinical trial, told NBC News, “We expand them from a million cells to several billion cells.”

The results of the trial were presented at the ESMO Congress 2022 meeting in Paris on Saturday.

To base their hypothesis, the doctors conducted a random trail and assigned 168 patients with metastatic melanoma to receive either TIL treatment or the current standard treatment—an&nbsp;immunotherapy drug&nbsp;called ipilimumab.

Ipilimumab treatment is used in people who don’t respond to a first-line treatment called anti-PD-1 therapy. Notably, all of the patients in the trial had not responded to that treatment.

After observing for three years, the scientists found that people on TIL therapy had a 50% reduction in disease progression and death compared to those who were treated with ipilimumab.&nbsp;

20 per cent of people on TIL therapy saw their tumours disappear completely, compared to 7 per cent in the ipilimumab group.

Though they are still being observed, the median survival time of cancer patients who received TIL therapy was found to be over two years, compared to just over 1.5 years on ipilimumab therapy, researchers found.

(With inputs from agencies)

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

&nbsp;

Researchers have discovered a new treatment for advanced melanoma during the Phase 3 clinical trial. They claim that it is far more effective than the existing leading therapy for metastatic melanoma.

Researchers have discovered a new treatment for advanced melanoma during the Phase 3 clinical trial. They claim that it is far more effective than the existing leading therapy for metastatic melanoma. The scientists at the Netherlands Cancer Institute said that the new treatment uses a patient’s own immune cells to fight cancer, and added that its therapy is similar to another type of treatment that has proven to be highly effective for blood cancers, called CAR-T therapy. Under CAR-T therapy, patients’ T-cells are harvested and modified in the lab into cancer fighters. These modified cells are then infused back into the patient. Similarly in the melanoma trial, the researchers used an approach called TIL therapy, which involves harvesting a patient’s immune cells—tumour-infiltrating lymphocytes, which are taken from the tumour. But instead of modifying these tumour cells in the lab like the CAR-T therapy, they’re simply amplified to produce billions of immune cells. Those amplified immune cells are then injected back into the patient’s blood, where they work to kill the cancer. Dr John Haanen, a medical oncologist at the Netherlands Cancer Institute, who led the new clinical trial, told NBC News, “We expand them from a million cells to several billion cells.” The results of the trial were presented at the ESMO Congress 2022 meeting in Paris on Saturday. To base their hypothesis, the doctors conducted a random trail and assigned 168 patients with metastatic melanoma to receive either TIL treatment or the current standard treatment—an immunotherapy drug called ipilimumab. Ipilimumab treatment is used in people who don’t respond to a first-line treatment called anti-PD-1 therapy. Notably, all of the patients in the trial had not responded to that treatment. After observing for three years, the scientists found that people on TIL therapy had a 50% reduction in disease progression and death compared to those who were treated with ipilimumab. 20 per cent of people on TIL therapy saw their tumours disappear completely, compared to 7 per cent in the ipilimumab group. Though they are still being observed, the median survival time of cancer patients who received TIL therapy was found to be over two years, compared to just over 1.5 years on ipilimumab therapy, researchers found. (With inputs from agencies) WATCH WION LIVE HERE

Scientists find novel cell based therapy to treat metastatic melanoma

The first jury trial in the United States involving the popular drug Zantac ended in a settlement worth more than $500,000. The four generic makers of the drug — Teva Pharmaceutical Industries Ltd., Perrigo Co., Sun Pharmaceutical Industries Inc. and Dr. Reddy’s Laboratories Inc — agreed to settle with the plaintiff Joseph Bayer after allegations that Zantac was responsible for causing esophageal cancer.&nbsp;

Bayer sued the generic drug makers alleging that the ranitidine formula of Zantac caused cancer in his system. The drug is currently not available in the market after the Food and Drug Administration (FDA) recalled it completely in 2020 after finding a contaminant known as N-Nitrosodimethylamine (NDMA).&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/south-asia/imf-announces-agreement-for-29bn-sri-lanka-bailout-511949" hreflang="en">Sri Lanka and IMF reach staff-level agreement for $2.9 billion bailout loan</a>

This was the first among over 3700 cases filed, both on the federal and state level,&nbsp;against the drug to go to a jury trial. However, the case against the generic makers and the two brand-name Zantac manufacturers — GlaxoSmithKline, Pfizer and Boehringer Ingelheim — were completely dropped.

According to Bloomberg, the plaintiffs in most of the lawsuits against Zantac have alleged that the company knew about the NMDA formation. They have alleged that ranitidine degrades due to humid conditions and although&nbsp;makers were aware of the phenomenon, they did not make it public.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/chinese-city-chengdu-announces-mass-covid-19-testing-amid-rising-cases-511959">Chinese city Chengdu announces mass COVID-19 testing amid rising cases</a>

The drug was first launched in 1983 as a histamine-2 (H2) blocker prescription drug and in a few years, it became extremely popular in the United States. In 1995, it received permission to become an over-the-counter drug and even after the official recall, it was relaunched as Pepcid and Pepcid AC with famotidine replacing the ranitidine.&nbsp;

WATCH WION LIVE HERE -

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

The first jury trial in the United States involving the popular drug Zantac ended in a settlement worth more than $500,000. The four generic makers of the drug — Teva Pharmaceutical Industries Ltd.

The first jury trial in the United States involving the popular drug Zantac ended in a settlement worth more than $500,000. The four generic makers of the drug — Teva Pharmaceutical Industries Ltd., Perrigo Co., Sun Pharmaceutical Industries Inc. and Dr. Reddy’s Laboratories Inc — agreed to settle with the plaintiff Joseph Bayer after allegations that Zantac was responsible for causing esophageal cancer. Bayer sued the generic drug makers alleging that the ranitidine formula of Zantac caused cancer in his system. The drug is currently not available in the market after the Food and Drug Administration (FDA) recalled it completely in 2020 after finding a contaminant known as N-Nitrosodimethylamine (NDMA). Also read | Sri Lanka and IMF reach staff-level agreement for $2.9 billion bailout loan This was the first among over 3700 cases filed, both on the federal and state level, against the drug to go to a jury trial. However, the case against the generic makers and the two brand-name Zantac manufacturers — GlaxoSmithKline, Pfizer and Boehringer Ingelheim — were completely dropped. According to Bloomberg, the plaintiffs in most of the lawsuits against Zantac have alleged that the company knew about the NMDA formation. They have alleged that ranitidine degrades due to humid conditions and although makers were aware of the phenomenon, they did not make it public. Also read | Chinese city Chengdu announces mass COVID-19 testing amid rising cases The drug was first launched in 1983 as a histamine-2 (H2) blocker prescription drug and in a few years, it became extremely popular in the United States. In 1995, it received permission to become an over-the-counter drug and even after the official recall, it was relaunched as Pepcid and Pepcid AC with famotidine replacing the ranitidine. WATCH WION LIVE HERE -

First lawsuit accusing Zantac of causing cancer ends in $500,000 settlement

An exclusive report by The Guardian has revealed that Black and Asian people in England have to wait longer for a cancer diagnosis than white people. According to a “disturbing” analysis of National Health Service (NHS) waiting times, some of them are forced to wait an extra six weeks for a diagnosis.

University of Exeter and The Guardian reviewed the world’s largest primary care database and discovered that minority ethnic patients wait longer than white patients in six of seven cancers studied. A delayed diagnosis leaves patients with fewer treatment options as in this case treatments might become less effective.&nbsp;

Also Read |&nbsp;<a href="https://www.wionews.com/world/scientists-develop-microrobots-that-surround-a-cancer-cell-and-kill-it-498833">Scientists develop microrobots that surround a cancer cell and kill it</a>

As per The Guardian - The analysis of 126,000 cancer cases over a decade found the median time between a white person first presenting symptoms to a GP and getting diagnosed is 55 days. For Asian people, it is 60 days (9% longer). For black people, it is 61 days (11% longer).

The University of Exeter looked at 126,000 cancer cases in England between 2006 and 2016. The data covered the four most common cancers – lung, breast, prostate and colorectal – and three commonly diagnosed in ethnic minorities: oesophagogastric, myeloma and ovarian.

An earlier research had already established that ethnic minorities suffer worse outcomes when it comes to certain cancers in England and are less likely to report a positive healthcare experience.

The differences in wait time for a diagnosis are particularly stark for some cancers. A white man for oesophagogastric cancer – of the stomach or oesophagus, is likely to get a diagnosis within 53 days of reporting the symptoms. However, for Asians it is 100 days. In myeloma, the third most common type of blood cancer, the median diagnosis wait time for white people is 93 days. For black people, it is 127 days.

Experts say it is important to understand why are ethnic inequalities in healthcare happening, endangering their lives.&nbsp;“We urgently need to address these underlying factors holding black and Asian patients back from getting a fair chance when it comes to fighting cancer," Jabeer Butt, the chief executive of the Race Equality Foundation, was quoted as saying by The Guardian.

Also Read |&nbsp;<a href="https://www.wionews.com/science/good-news-starchy-green-bananas-can-reduce-risk-of-cancer-study-finds-500727">Good news! Starchy green bananas can reduce risk of cancer, study finds</a>

Michelle Mitchell, the chief executive of Cancer Research UK, which funded the research, said that added wait time means additional stress and anxiety for the ethnic minority patients.&nbsp;

Guardian analysed the data and came up with astounding figures. It said that in six of the seven cancers analysed, black or Asian patients waited longer for a diagnosis than white patients. Lung cancer was the exception where the median wait time was 103 days for black patients, 115 for Asian patients, and 129 for white patients. The median myeloma diagnosis wait time for black people was 37% longer than for white people.

&nbsp;

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

An exclusive report by The Guardian has revealed that Black and Asian people in England have to wait longer for a cancer diagnosis than white people. According to a “disturbing” analysis of National Health Service (NHS) waiting times, some of them are forced to wait an extra six weeks for a diagnosis.

An exclusive report by The Guardian has revealed that Black and Asian people in England have to wait longer for a cancer diagnosis than white people. According to a “disturbing” analysis of National Health Service (NHS) waiting times, some of them are forced to wait an extra six weeks for a diagnosis. University of Exeter and The Guardian reviewed the world’s largest primary care database and discovered that minority ethnic patients wait longer than white patients in six of seven cancers studied. A delayed diagnosis leaves patients with fewer treatment options as in this case treatments might become less effective. Also Read | Scientists develop microrobots that surround a cancer cell and kill it As per The Guardian - The analysis of 126,000 cancer cases over a decade found the median time between a white person first presenting symptoms to a GP and getting diagnosed is 55 days. For Asian people, it is 60 days (9% longer). For black people, it is 61 days (11% longer). The University of Exeter looked at 126,000 cancer cases in England between 2006 and 2016. The data covered the four most common cancers – lung, breast, prostate and colorectal – and three commonly diagnosed in ethnic minorities: oesophagogastric, myeloma and ovarian. An earlier research had already established that ethnic minorities suffer worse outcomes when it comes to certain cancers in England and are less likely to report a positive healthcare experience. The differences in wait time for a diagnosis are particularly stark for some cancers. A white man for oesophagogastric cancer – of the stomach or oesophagus, is likely to get a diagnosis within 53 days of reporting the symptoms. However, for Asians it is 100 days. In myeloma, the third most common type of blood cancer, the median diagnosis wait time for white people is 93 days. For black people, it is 127 days. Experts say it is important to understand why are ethnic inequalities in healthcare happening, endangering their lives. “We urgently need to address these underlying factors holding black and Asian patients back from getting a fair chance when it comes to fighting cancer," Jabeer Butt, the chief executive of the Race Equality Foundation, was quoted as saying by The Guardian. Also Read | Good news! Starchy green bananas can reduce risk of cancer, study finds Michelle Mitchell, the chief executive of Cancer Research UK, which funded the research, said that added wait time means additional stress and anxiety for the ethnic minority patients. Guardian analysed the data and came up with astounding figures. It said that in six of the seven cancers analysed, black or Asian patients waited longer for a diagnosis than white patients. Lung cancer was the exception where the median wait time was 103 days for black patients, 115 for Asian patients, and 129 for white patients. The median myeloma diagnosis wait time for black people was 37% longer than for white people.

Minority ethnic cancer patients in UK wait much longer than their white counterparts for a diagnosis: Study

A new study has shown that a new cancer treatment can stop the disease from advancing in patients who are out of options, which includes being resistant to immunotherapy.

Some tumours can evolve to resist immunotherapy which uses the immune system to target and kill cancer cells.

Combining immunotherapy with guadecitabine can reverse cancer’s resistance to the former, according to oncologists in the UK.

The results published in the Journal for ImmunoTherapy of Cancer show that the combination of pembrolizumab with guadecitabine halted the advance of cancer in more than a third of patients enrolled in the early phase 1 trial.

Experts at the Institute of Cancer Research and Royal Marsden NHS foundation trust said that the dual combination could become an effective new weapon against several forms of cancer.

<a href="https://www.wionews.com/world/scientists-develop-microrobots-that-surround-a-cancer-cell-and-kill-it-498833">Also read |&nbsp;Scientists develop microrobots that surround a cancer cell and kill it</a>

According to the study’s chief investigator, Prof Johann de Bono, “I think one of the most important things about this trial is that we used multiple different methods to look for changes in the immune system, robustly showing that it was being influenced by the combination treatment.”

“In the long term we hope that if these effects are confirmed in other patient groups and future studies, guadecitabine and pembrolizumab could help to tackle some of the resistance to immunotherapy we see in too many types of cancer,” he added.

30 out of 34 patients, experienced no tumour progression for 24 weeks or more after getting injected with guadecitabine for four days in a row every three weeks for three years.

Lung and skin cancer patients especially benefit from pembrolizumab which is an immune checkpoint inhibitor drug.

“Immunotherapy has shown amazing promise in cancer care over the last decade, but it doesn’t work well in all cancers and cancers can often become resistant. This combination might be a way to target their cancer even after it has stopped responding to immunotherapy,” said the study's lead author Anna Minchom, a clinical scientist at the Institute of Cancer Research and a consultant medical oncologist at the Royal Marsden.

Before the trial, three-fifths of the group (60 per cent) were resistant to immunotherapy but this decreased to 37 per cent after it concluded.

(With inputs from agencies)

Watch WION's live TV here:

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false"><iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

&nbsp;

A new study has shown that a new cancer treatment can stop the disease from advancing in patients who are out of options, which includes being resistant to immunotherapy.

A new study has shown that a new cancer treatment can stop the disease from advancing in patients who are out of options, which includes being resistant to immunotherapy. Some tumours can evolve to resist immunotherapy which uses the immune system to target and kill cancer cells. Combining immunotherapy with guadecitabine can reverse cancer’s resistance to the former, according to oncologists in the UK. The results published in the Journal for ImmunoTherapy of Cancer show that the combination of pembrolizumab with guadecitabine halted the advance of cancer in more than a third of patients enrolled in the early phase 1 trial. Experts at the Institute of Cancer Research and Royal Marsden NHS foundation trust said that the dual combination could become an effective new weapon against several forms of cancer. Also read | Scientists develop microrobots that surround a cancer cell and kill it According to the study’s chief investigator, Prof Johann de Bono, “I think one of the most important things about this trial is that we used multiple different methods to look for changes in the immune system, robustly showing that it was being influenced by the combination treatment.” “In the long term we hope that if these effects are confirmed in other patient groups and future studies, guadecitabine and pembrolizumab could help to tackle some of the resistance to immunotherapy we see in too many types of cancer,” he added. 30 out of 34 patients, experienced no tumour progression for 24 weeks or more after getting injected with guadecitabine for four days in a row every three weeks for three years. Lung and skin cancer patients especially benefit from pembrolizumab which is an immune checkpoint inhibitor drug. “Immunotherapy has shown amazing promise in cancer care over the last decade, but it doesn’t work well in all cancers and cancers can often become resistant. This combination might be a way to target their cancer even after it has stopped responding to immunotherapy,” said the study's lead author Anna Minchom, a clinical scientist at the Institute of Cancer Research and a consultant medical oncologist at the Royal Marsden. Before the trial, three-fifths of the group (60 per cent) were resistant to immunotherapy but this decreased to 37 per cent after it concluded. (With inputs from agencies) Watch WION's live TV here: ×

Study shows new cancer treatment can stop the disease advancing in patients who are resistant to immunotherapy

A cancer study has revealed that smoking, drinking alcohol, being overweight and other risk factors are responsible for almost half of all cancer deaths worldwide. While there has been uncertainty over the exact cause of cancer, researchers at the University of Washington’s school of medicine have worked out how risk factors contribute to cancer deaths globally, The Guardian reported.

According to the study, smoking, alcohol use, and a high body mass index (BMI) are the topmost contributors to cancer deaths. In total, risk factors are responsible for nearly 4.45m cancer deaths a year, according to the findings published in the Lancet that used the Global Burden of Diseases, Injuries, and Risk Factors (GBD) 2019 study.

Also Read |&nbsp;<a href="https://www.wionews.com/world/scientists-develop-microrobots-that-surround-a-cancer-cell-and-kill-it-498833">Scientists develop microrobots that surround a cancer cell and kill it</a>

This means that 44.4% of all cancer deaths worldwide were a result of these factors. Half of all male cancer deaths in 2019 (50.6%, or 2.88m) were due to estimated risk factors, compared with more than a third of all female cancer deaths (36.3%, or 1.58m).

Smoking was the leading cause of deaths in both sexes, with tracheal, bronchus and lung cancer on top. These account for 36.9% of all cancer deaths attributable to risk factors.

"Smoking continues to be the leading risk factor for cancer globally, with other substantial contributors to cancer burden varying. Our findings can help policymakers and researchers identify key risk factors that could be targeted in efforts to reduce deaths and ill health from cancer regionally, nationally, and globally," Dr Christopher Murray, &nbsp;co-senior author of the study, said.

Also Read |&nbsp;<a href="https://www.wionews.com/science/a-lot-of-happy-tears-cancer-disappears-in-every-patient-in-a-small-drug-trial-485905">'A lot of happy tears': Cancer 'disappears' in every patient in a small drug trial</a>

Cervical cancer (17.9%), colon and rectum cancer (15.8%) and breast cancer (11%) were next in the list for women. In men, it was colon and rectum cancer (13.3%), oesophageal cancer (9.7%) and stomach cancer (6.6%).

Experts suggest that even though it is not possible to prevent all cases of cancer, eating healthy, stopping smoking, reducing alcohol intake and exercising can help lower the future burden of cancer.&nbsp;

(With inputs from agencies)

&nbsp;

&nbsp;

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

A cancer study has revealed that smoking, drinking alcohol, being overweight and other risk factors are responsible for almost half of all cancer deaths worldwide.

A cancer study has revealed that smoking, drinking alcohol, being overweight and other risk factors are responsible for almost half of all cancer deaths worldwide. While there has been uncertainty over the exact cause of cancer, researchers at the University of Washington’s school of medicine have worked out how risk factors contribute to cancer deaths globally, The Guardian reported. According to the study, smoking, alcohol use, and a high body mass index (BMI) are the topmost contributors to cancer deaths. In total, risk factors are responsible for nearly 4.45m cancer deaths a year, according to the findings published in the Lancet that used the Global Burden of Diseases, Injuries, and Risk Factors (GBD) 2019 study. Also Read | Scientists develop microrobots that surround a cancer cell and kill it This means that 44.4% of all cancer deaths worldwide were a result of these factors. Half of all male cancer deaths in 2019 (50.6%, or 2.88m) were due to estimated risk factors, compared with more than a third of all female cancer deaths (36.3%, or 1.58m). Smoking was the leading cause of deaths in both sexes, with tracheal, bronchus and lung cancer on top. These account for 36.9% of all cancer deaths attributable to risk factors. "Smoking continues to be the leading risk factor for cancer globally, with other substantial contributors to cancer burden varying. Our findings can help policymakers and researchers identify key risk factors that could be targeted in efforts to reduce deaths and ill health from cancer regionally, nationally, and globally," Dr Christopher Murray, co-senior author of the study, said. Also Read | 'A lot of happy tears': Cancer 'disappears' in every patient in a small drug trial Cervical cancer (17.9%), colon and rectum cancer (15.8%) and breast cancer (11%) were next in the list for women. In men, it was colon and rectum cancer (13.3%), oesophageal cancer (9.7%) and stomach cancer (6.6%). Experts suggest that even though it is not possible to prevent all cases of cancer, eating healthy, stopping smoking, reducing alcohol intake and exercising can help lower the future burden of cancer. (With inputs from agencies)

Smoking, alcohol, high BMI: Study reveals risk factors responsible for almost half of cancer deaths

Waste pickers at Kenya's Dandora dumpsite are going through some severe health issues like cancer and infertility. On a daily basis nearly about 10,000 women and children work through the garbage each day.

Kenya: Toxic dump affects reproductive health of waste pickers

US pharmaceutical giant Johnson & Johnson on Thursday announced that it will be discontinuing the sales of its controversial talc-based baby powder globally in 2023.

US pharmaceutical giant Johnson & Johnson on Thursday announced that it will be discontinuing the sales of its controversial talc-based baby powder globally in 2023. The announcement to cease the product sales globally comes two years after J&J halted its sales in USA and Canada. In a statement, the company added that it will be moving from talc-based powder to cornstarch-based baby powder. "As part of a worldwide portfolio assessment, we have made the commercial decision to transition to an all cornstarch-based baby powder portfolio. As a result of this transition, talc-based J&J Baby Powder will be discontinued globally in 2023," read the company's statement. For years, J&J talcum powders, especially baby powders have been at the centre of controversy. Over 38,000 lawsuits have been filed by the consumers as well as the survivors, some of whom allege they were hurt by the use of the product. Some of the lawsuits claim the powder contained cancer-causing material like asbestos. Read more: Amid cancer scare, drug regulator body asks Johnson & Johnson not to use baby powder raw material However, the pharma giant, in its statement continued to take the line that its product was safe, despite the termination of the sales. Watch: Johnson & Johnson to end global sales of controversial talc-based baby powder "Our position on the safety of our cosmetic talc remains unchanged. We stand firmly behind the decades of independent scientific analysis by medical experts around the world that confirms talc-based J&J Baby Powder is safe, does not contain asbestos, and does not cause cancer." A Reuters report previously revealed that J&J knew about the harmful effects of its product, according to internal memos circulated within the company. However, it doubled down on its sales by targeting the African American and overweight women market. J&J exploiting legal loopholes Moreover, to avoid the lengthy lawsuits, J&J, in February this year, used a manoeuvre called 'Texas two-step' to receive a stay on the complaints. Reportedly, J&J unloaded the blame of its baby powder on a newly spawned subsidiary named LTL Management. The said company filed for bankruptcy and managed to receive the court's nod for it. It is pertinent to note that in case of bankruptcy, individual lawsuits are put on hold and thus J&J managed to evade the legal process by using a loophole. Read more: Johnson & Johnson recalls several aerosol sunscreen products after detecting cancer-causing agent (With inputs from agencies) WATCH WION LIVE HERE:

Johnson & Johnson to stop selling its talc-based baby powder globally in 2023 as lawsuits mount

Let us take a look at stories generating interest across WION's social media channels.

Trending On WION: Johnson & Johnson to stop selling its 'cancer causing' talc-based baby powder

After a four-year struggle with breast cancer, track legend Lydia de Vega, once regarded as Asia's fastest woman and one of the Philippines' most accomplished and adored athletes passed away at 57.&nbsp;

In a statement, President Ferdinand Marcos Jr said "De Vega has run her last race."

"She has finished her contest. She has fought a good fight. Let us pray for her peace," he said.

"She fought the very good fight and is now at peace," de Vega's daughter Stephanie De Koenigswarter said in a Facebook&nbsp;post late Wednesday.&nbsp;

Throughout her career, De Vega earned 15 gold medals, including nine at the South-east Asian Games.

When she won gold medals in the 200 and 400 metres at the 1981 Manila SEA Games at the age of just 16, she quickly rose to fame on the track in the Philippines.

She went on to dominate the 200m in the 1983 and 1987 SEA Games, and then rule the 100m in the 1987, 1991 and 1993 SEA Games.

Asia's sports fans know De Vega most for her epic battle with India's Pilavullakandi Thekkeparambil Usha, or P.T. Usha.

<img alt="Filipino athlete actress Lydia De Vega raises her hand in triumph after winning the Asiad ‘82 women’s 100 metre race. On the far right (No.488) is P.T. Usha of India, who finished second to add to India’s silver medal tally at the Nineth Asian Games held in New Delhi on November 27, 1982." data-entity-type="file" data-entity-uuid="e4806bd7-7fd1-43a5-9e6e-2e581fc352cd" src="//cdn.wionews.com/sites/default/files/inline-images/HSP100901.jpg" />

Filipino athlete actress Lydia De Vega raises her hand in triumph after winning the Asiad ‘82 women’s 100 metre race. On the far right (No.488) is P.T. Usha of India, who finished second to add to India’s silver medal tally at the Nineth Asian Games held in New Delhi on November 27, 1982. Photo credits: SPORTSTAR

The first time the two faced off was in the 100m at the 1982 Asian Games, where de Vega won after taking the lead halfway through.

However, Usha had reached the pinnacle of her career by 1985, winning five gold medals at the Asian Championships in Indonesia. De Vega on the other hand won a bronze medal.&nbsp;

Then, in the 1986 Seoul Asian Games, de Vega once again underlined her dominance in her preferred event: the one-kilometer race, while Usha—known as the "Payyoli Express"—dominated the 400-meter and 400-meter hurdles.

P.T. Usha took to Twitter to share her condolences.&nbsp;

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
Deeply saddened on losing my athletics counterpart, a fierce competitor and good friend Lydia de Vega yesterday. She lost her life race to breast cancer but will always be remembered as a champion of life. My deepest condolences to her family! <a href="https://t.co/RoyHdBEZH5">pic.twitter.com/RoyHdBEZH5</a>
— P.T. USHA (@PTUshaOfficial) <a href="https://twitter.com/PTUshaOfficial/status/1557600847898771456?ref_src=twsrc%5Etfw">August 11, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

(With inputs from agencies)

After a four-year struggle with breast cancer, track legend Lydia de Vega, once regarded as Asia's fastest woman and one of the Philippines' most accomplished and adored athletes passed away at 57.

After a four-year struggle with breast cancer, track legend Lydia de Vega, once regarded as Asia's fastest woman and one of the Philippines' most accomplished and adored athletes passed away at 57. In a statement, President Ferdinand Marcos Jr said "De Vega has run her last race." "She has finished her contest. She has fought a good fight. Let us pray for her peace," he said. "She fought the very good fight and is now at peace," de Vega's daughter Stephanie De Koenigswarter said in a Facebook post late Wednesday. Throughout her career, De Vega earned 15 gold medals, including nine at the South-east Asian Games. When she won gold medals in the 200 and 400 metres at the 1981 Manila SEA Games at the age of just 16, she quickly rose to fame on the track in the Philippines. She went on to dominate the 200m in the 1983 and 1987 SEA Games, and then rule the 100m in the 1987, 1991 and 1993 SEA Games. Asia's sports fans know De Vega most for her epic battle with India's Pilavullakandi Thekkeparambil Usha, or P.T. Usha. Filipino athlete actress Lydia De Vega raises her hand in triumph after winning the Asiad ‘82 women’s 100 metre race. On the far right (No.488) is P.T. Usha of India, who finished second to add to India’s silver medal tally at the Nineth Asian Games held in New Delhi on November 27, 1982. Photo credits: SPORTSTAR The first time the two faced off was in the 100m at the 1982 Asian Games, where de Vega won after taking the lead halfway through. However, Usha had reached the pinnacle of her career by 1985, winning five gold medals at the Asian Championships in Indonesia. De Vega on the other hand won a bronze medal. Then, in the 1986 Seoul Asian Games, de Vega once again underlined her dominance in her preferred event: the one-kilometer race, while Usha—known as the "Payyoli Express"—dominated the 400-meter and 400-meter hurdles. P.T. Usha took to Twitter to share her condolences. Deeply saddened on losing my athletics counterpart, a fierce competitor and good friend Lydia de Vega yesterday. She lost her life race to breast cancer but will always be remembered as a champion of life. My deepest condolences to her family! pic.twitter.com/RoyHdBEZH5 — P.T. USHA (@PTUshaOfficial) August 11, 2022 × (With inputs from agencies)

Asian 'track queen' and P.T. Usha's fierce rival on track, Lydia de Vega loses battle to cancer

A diagnosis of blood cancer can indeed be a shock to a patient. But there are those who calm themselves down and continue on their path with focus, defying odds to achieve a great feat. Tale of 17-year-old Pramita Tiwari certainly exemplifies the indomitable human spirit which many of us forget to find within ourselves. Pramita, a resident of Lucknow in north Indian state of Uttar Pradesh scored 97.75 per cent in Indian School Certificate (ISC) examination, all when she battled cancer.

Pramita started experiencing symptoms during Covid induced lockdowns. When her parents got her tested, the family came to know that she was suffering from Acute Minor Leukemia (blood cancer). Her parents stood by her side firmly and her treatment began. She received treatment in Lucknow and Gurugram.

"I didn't have a consistent schedule due to my untimely sickness &amp; hospital visits. However much I could read, I read with full concentration... my aim is to become a doctor," she said as quoted by ANI.

She has been quoted in media reports as saying that she studied even during her visits to hospital.

Times of India said that her school arranged online classes for her and even arranged for her to take her exam in Gurugram when she was receiving treatment.

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

WATCH WION LIVE HERE

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false"><iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

&nbsp;

A diagnosis of blood cancer can indeed be a shock to a patient. But there are those who calm themselves down and continue on their path with focus, defying odds to achieve a great feat.

A diagnosis of blood cancer can indeed be a shock to a patient. But there are those who calm themselves down and continue on their path with focus, defying odds to achieve a great feat. Tale of 17-year-old Pramita Tiwari certainly exemplifies the indomitable human spirit which many of us forget to find within ourselves. Pramita, a resident of Lucknow in north Indian state of Uttar Pradesh scored 97.75 per cent in Indian School Certificate (ISC) examination, all when she battled cancer. Pramita started experiencing symptoms during Covid induced lockdowns. When her parents got her tested, the family came to know that she was suffering from Acute Minor Leukemia (blood cancer). Her parents stood by her side firmly and her treatment began. She received treatment in Lucknow and Gurugram. "I didn't have a consistent schedule due to my untimely sickness & hospital visits. However much I could read, I read with full concentration... my aim is to become a doctor," she said as quoted by ANI. She has been quoted in media reports as saying that she studied even during her visits to hospital. Times of India said that her school arranged online classes for her and even arranged for her to take her exam in Gurugram when she was receiving treatment. You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here. WATCH WION LIVE HERE ×

Indian teen battles cancer and scores 97.75 per cent in ISC exams

A new study had some good news for people with a hereditary risk of cancer as it showed that a number of food items can diminish the danger considerably. The trial, which was conducted on 1000 people with a genetic condition known as Lynch Syndrome, showed that food items like cereals, oats and even green bananas can help him due to the presence of resistant starch.

Also read |&nbsp;<a href="https://www.wionews.com/india-news/this-indian-woman-is-breaking-gender-stereotypes-by-sporting-a-moustache-500709" hreflang="en">This Indian woman is breaking gender stereotypes by sporting a moustache</a>

The study was done over six years and except for cancers in the bowel, most other kinds of cancers were affected by a regular dose of resistant fibers. According to PA Media, the researchers are hopeful that the results will continue for around 10 years even after a person stops taking the fibers in their diets.

The study, which was published in Cancer Prevention Research, was conducted by researchers at the Universities of Newcastle and Leeds. John Mathers, professor of human nutrition at Newcastle University, led the study and he was quite hopeful about the results that it produced.

Also read |&nbsp;<a href="https://www.wionews.com/world/watch-severed-snakehead-found-in-airline-in-flight-meal-catering-suspended-500711" hreflang="en">Watch | Severed snakehead found in airline in-flight meal; catering suspended</a>

&nbsp;“We found that resistant starch reduces a range of cancers by over 60%. The effect was most obvious in the upper part of the gut. This is important as cancers of the upper GI tract are difficult to diagnose and often are not caught early on,”, he explained according to the PA Media report.

“Resistant starch can be taken as a powder supplement and is found naturally in peas, beans, oats and other starchy foods. The dose used in the trial is equivalent to eating a daily banana; before they become too ripe and soft, the starch in bananas resists breakdown and reaches the bowel where it can change the type of bacteria that live there,” he said while explaining their findings.

WATCH WION LIVE HERE -

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

A new study had some good news for people with a hereditary risk of cancer as it showed that a number of food items can diminish the danger considerably. The trial, which was conducted on 1000 people with a genetic condition known as Lynch Syndrome, showed that food items like cereals, oats and even green bananas can help him due to the presence of resistant starch.

A new study had some good news for people with a hereditary risk of cancer as it showed that a number of food items can diminish the danger considerably. The trial, which was conducted on 1000 people with a genetic condition known as Lynch Syndrome, showed that food items like cereals, oats and even green bananas can help him due to the presence of resistant starch. Also read | This Indian woman is breaking gender stereotypes by sporting a moustache The study was done over six years and except for cancers in the bowel, most other kinds of cancers were affected by a regular dose of resistant fibers. According to PA Media, the researchers are hopeful that the results will continue for around 10 years even after a person stops taking the fibers in their diets. The study, which was published in Cancer Prevention Research, was conducted by researchers at the Universities of Newcastle and Leeds. John Mathers, professor of human nutrition at Newcastle University, led the study and he was quite hopeful about the results that it produced. Also read | Watch | Severed snakehead found in airline in-flight meal; catering suspended “We found that resistant starch reduces a range of cancers by over 60%. The effect was most obvious in the upper part of the gut. This is important as cancers of the upper GI tract are difficult to diagnose and often are not caught early on,”, he explained according to the PA Media report. “Resistant starch can be taken as a powder supplement and is found naturally in peas, beans, oats and other starchy foods. The dose used in the trial is equivalent to eating a daily banana; before they become too ripe and soft, the starch in bananas resists breakdown and reaches the bowel where it can change the type of bacteria that live there,” he said while explaining their findings. WATCH WION LIVE HERE -

Good news! Starchy green bananas can reduce risk of cancer, study finds

Jared Kushner is an important aide during former United States president Donald Trump’s time at the White House. The businessman and investor, who is married to Trump’s daughter Ivanka – was involved in a number of decisions taken during the tenure and even acted as the country’s representative in the Middle East during a handful of peace talks. However, his health took a hit during that time period and in a memoir which will be published in August this year, Kushner wrote that he suffered from thyroid cancer in 2019 but that information was not disclosed to the public.

Also read |&nbsp;<a href="https://www.wionews.com/world/no-unity-in-european-union-member-nations-oppose-eus-gas-curb-proposal-500825" hreflang="en">No unity in European Union? Member nations oppose EU's gas curb plans</a>

In the memoir Breaking History: A White House Memoir, to be published on 23 August, Kushner wrote that he was told about the condition by White House physician Sean Conley. He underwent the surgery later that year and that was crucial in keeping his cancer under control.

While the news was kept under wraps at the moment, Reuters quoted Kushner as saying in the memoir that he was surprised by the fact that Trump knew all about his diagnosis.

Also read |&nbsp;<a href="https://www.wionews.com/south-asia/former-president-gotabaya-rajapaksa-will-return-to-sri-lanka-says-cabinet-spokesperson-500774" hreflang="en">Former president Gotabaya Rajapaksa will return to Sri Lanka, says cabinet spokesperson</a>

&nbsp;“The day before the surgery, Trump called me into the Oval Office and motioned for his team to close the door. ‘Are you nervous about the surgery?’ he asked.”

Kushner did not tell Trump about it and when he asked how the former president knew about his surgery, Trump said: “I’m the president. I know everything. I understand that you want to keep these things quiet. I like to keep things like this to myself as well. You’ll be just fine. Don’t worry about anything with work. We have everything covered here.”

Jared Kushner is an important aide during former United States president Donald Trump’s time at the White House. The businessman and investor, who is married to Trump’s daughter Ivanka – was involved in a number of decisions taken during the tenure and even acted as the country’s representative in the Middle East during a handful of peace talks.

Jared Kushner is an important aide during former United States president Donald Trump’s time at the White House. The businessman and investor, who is married to Trump’s daughter Ivanka – was involved in a number of decisions taken during the tenure and even acted as the country’s representative in the Middle East during a handful of peace talks. However, his health took a hit during that time period and in a memoir which will be published in August this year, Kushner wrote that he suffered from thyroid cancer in 2019 but that information was not disclosed to the public. Also read | No unity in European Union? Member nations oppose EU's gas curb plans In the memoir Breaking History: A White House Memoir, to be published on 23 August, Kushner wrote that he was told about the condition by White House physician Sean Conley. He underwent the surgery later that year and that was crucial in keeping his cancer under control. While the news was kept under wraps at the moment, Reuters quoted Kushner as saying in the memoir that he was surprised by the fact that Trump knew all about his diagnosis. Also read | Former president Gotabaya Rajapaksa will return to Sri Lanka, says cabinet spokesperson “The day before the surgery, Trump called me into the Oval Office and motioned for his team to close the door. ‘Are you nervous about the surgery?’ he asked.” Kushner did not tell Trump about it and when he asked how the former president knew about his surgery, Trump said: “I’m the president. I know everything. I understand that you want to keep these things quiet. I like to keep things like this to myself as well. You’ll be just fine. Don’t worry about anything with work. We have everything covered here.”

Jared Kushner was treated for thyroid cancer during his time in White House

US President Joe Biden made a shocking revelation that he has cancer, sending shock waves across the country.

While giving a speech about global warming where he talked about the side effects of emissions from oil refineries near his hometown in Somerset, Massachusetts, Biden said, “That’s why I and so damn many other people I grew up with have cancer and why for the longest time Delaware had the highest cancer rate in the nation.”

The video was posted on Twitter by RNC Research, an account managed by the Republican National Committee.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
This is what the President was referring to. <a href="https://t.co/8F0NGTei6f">https://t.co/8F0NGTei6f</a>
— Andrew Bates (@AndrewJBates46) <a href="https://twitter.com/AndrewJBates46/status/1549853062596009986?ref_src=twsrc%5Etfw">July 20, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

Though the remark seemed non-serious, it created head waves on social media as soon as a video of his statement went viral. Many wondered if the president was speaking the truth or was it one of his infamous gaffes.

Before the speculations could become rife, the White House came out with a clarification saying that the 79-year-old leader was referring to skin cancer treatment he had taken before assuming the office in January last year.

White House spokesman Andrew Bates retweeted a tweet from Washington Post columnist Glenn Kessler who noted that Biden had “non-melanoma skin cancers” removed before he took office.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
This is what the President was referring to. <a href="https://t.co/8F0NGTei6f">https://t.co/8F0NGTei6f</a>
— Andrew Bates (@AndrewJBates46) <a href="https://twitter.com/AndrewJBates46/status/1549853062596009986?ref_src=twsrc%5Etfw">July 20, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

He even slammed the RNC Research for taking his remarks out of context to present as if Biden had hidden the fact that he has cancer.

According to New York Post, Biden’s physician Dr Kevin O’Connor had last year issued a health report that didn’t refer to the president as suffering from any current cancers.

&nbsp;

The report mentioned Biden’s skin cancer to time in the sun, rather than exposure to chemicals used by the oil industry.

“It is well-established that President Biden did spend a good deal of time in the sun in his youth,” O’Connor wrote of his patient, a former swimming pool lifeguard, reports the US-based news outlet.

(With inputs from agencies)

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

US President Joe Biden made a shocking revelation that he has cancer, sending shock waves across the country. While giving a speech about global warming where he talked about the side effects of emissions from oil refineries near his hometown in Somerset, Massachusetts, Biden said, “That’s why I and so damn many other people I grew up with have cancer and why for the longest time Delaware had the highest cancer rate in the nation.

US President Joe Biden made a shocking revelation that he has cancer, sending shock waves across the country. While giving a speech about global warming where he talked about the side effects of emissions from oil refineries near his hometown in Somerset, Massachusetts, Biden said, “That’s why I and so damn many other people I grew up with have cancer and why for the longest time Delaware had the highest cancer rate in the nation.” The video was posted on Twitter by RNC Research, an account managed by the Republican National Committee. This is what the President was referring to. https://t.co/8F0NGTei6f — Andrew Bates (@AndrewJBates46) July 20, 2022 × Though the remark seemed non-serious, it created head waves on social media as soon as a video of his statement went viral. Many wondered if the president was speaking the truth or was it one of his infamous gaffes. Before the speculations could become rife, the White House came out with a clarification saying that the 79-year-old leader was referring to skin cancer treatment he had taken before assuming the office in January last year. White House spokesman Andrew Bates retweeted a tweet from Washington Post columnist Glenn Kessler who noted that Biden had “non-melanoma skin cancers” removed before he took office. This is what the President was referring to. https://t.co/8F0NGTei6f — Andrew Bates (@AndrewJBates46) July 20, 2022 × He even slammed the RNC Research for taking his remarks out of context to present as if Biden had hidden the fact that he has cancer. According to New York Post, Biden’s physician Dr Kevin O’Connor had last year issued a health report that didn’t refer to the president as suffering from any current cancers. The report mentioned Biden’s skin cancer to time in the sun, rather than exposure to chemicals used by the oil industry. “It is well-established that President Biden did spend a good deal of time in the sun in his youth,” O’Connor wrote of his patient, a former swimming pool lifeguard, reports the US-based news outlet. (With inputs from agencies) WATCH WION LIVE HERE

Does Joe Biden have cancer? White House clarifies

This new track and trace technology may help to identify tumour spread in breast cancer patients. Doctors at London's St Georges Hospital are using this technology. Doctors are using a whole system called Endomag. Surgeons remove primary breast tumour through surgery, radiotherapy, and chemotherapy. Then doctors check whether cancer has been treated or if it has spread. Doctors use a magnetic liquid tracer, magtrace, to follow this process.

Tech in Trend: New technology may help to identify tumour spread in breast cancer patients

Researchers at the Physical Intelligence Department of Max Planck Institute in Germany have made a breakthrough that can help fight cancer. Reportedly, the scientists at the institute, combining elements of robotics and biology have developed magnetically-controlled microscopic robots that can reach tumour cells and battle cancer.&nbsp;

The scientists used E.coli bacteria, often dubbed 'superhero of the microbial world' for the process. The E.coli bacteria can easily traverse through material ranging from liquids to highly viscous tissues, making it the ideal choice for the experiment.&nbsp;

The scientists attached magnetic nanoparticles to this bacterium and when exposed to a magnetic field, managed to enhance its speed, allowing it to reach the desired spot quicker. Meanwhile, spherical-shaped carriers called liposomes that contain the medication were also attached. After reaching the tumour spot, the microrobots grow there and start their 'miracle' work.&nbsp;
<img alt=" Bacterial biohybrids" data-caption="&amp;nbsp;Bacterial biohybrids" data-entity-type="file" data-entity-uuid="48dfba2f-ea93-452f-b3a5-4cb70f052c67" src="//cdn.wionews.com/sites/default/files/inline-images/content_Schematics_1.jpg" />
Birgül Akolpoglu, a PhD student and the first author of the research decoded the process by stating that these biohybrid microrobots can be used to awaken the immune system of the patients, which will help fight the tumour cells and simultaneously increase the effect of cancer drugs.&nbsp;

“Imagine we would inject such bacteria-based microrobots into a cancer patient’s body. With a magnet, we could precisely steer the particles towards the tumour. Once enough microrobots surround the tumour, we point a laser at the tissue and by that trigger the drug release. Now, not only is the immune system triggered to wake up, but the additional drugs also help destroy the tumour,” Akolpoglu was quoted as saying by the official Max Planck Institute website.&nbsp;

It is pertinent to note that bacteria are drawn to areas of low oxygen levels and high acidity in the body; both of which are prevalent near a tumour. Thus, scientists have managed to use both, the natural and programmed qualities of modified E.Coli bacteria to tackle the cancer tumour.&nbsp;

“Bacteria-based biohybrid microrobots with medical functionalities could one-day battle cancer more effectively. It is a new therapeutic approach not too far away from how we treat cancer today,” added co-author Dr Metin Sitti. 
&nbsp;

(With inputs from agencies)

WATCH WION LIVE HERE:

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" loading="”lazy”" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1  width=&quot;100%&quot;"></iframe>

Researchers at the Physical Intelligence Department of Max Planck Institute in Germany have made a breakthrough that can help fight cancer. Reportedly, the scientists at the institute, combining elements of robotics and biology have developed magnetically-controlled microscopic robots that can reach tumour cells and battle cancer.

Researchers at the Physical Intelligence Department of Max Planck Institute in Germany have made a breakthrough that can help fight cancer. Reportedly, the scientists at the institute, combining elements of robotics and biology have developed magnetically-controlled microscopic robots that can reach tumour cells and battle cancer. The scientists used E.coli bacteria, often dubbed 'superhero of the microbial world' for the process. The E.coli bacteria can easily traverse through material ranging from liquids to highly viscous tissues, making it the ideal choice for the experiment. The scientists attached magnetic nanoparticles to this bacterium and when exposed to a magnetic field, managed to enhance its speed, allowing it to reach the desired spot quicker. Meanwhile, spherical-shaped carriers called liposomes that contain the medication were also attached. After reaching the tumour spot, the microrobots grow there and start their 'miracle' work. Birgül Akolpoglu, a PhD student and the first author of the research decoded the process by stating that these biohybrid microrobots can be used to awaken the immune system of the patients, which will help fight the tumour cells and simultaneously increase the effect of cancer drugs. “Imagine we would inject such bacteria-based microrobots into a cancer patient’s body. With a magnet, we could precisely steer the particles towards the tumour. Once enough microrobots surround the tumour, we point a laser at the tissue and by that trigger the drug release. Now, not only is the immune system triggered to wake up, but the additional drugs also help destroy the tumour,” Akolpoglu was quoted as saying by the official Max Planck Institute website. It is pertinent to note that bacteria are drawn to areas of low oxygen levels and high acidity in the body; both of which are prevalent near a tumour. Thus, scientists have managed to use both, the natural and programmed qualities of modified E.Coli bacteria to tackle the cancer tumour. “Bacteria-based biohybrid microrobots with medical functionalities could one-day battle cancer more effectively. It is a new therapeutic approach not too far away from how we treat cancer today,” added co-author Dr Metin Sitti. (With inputs from agencies) WATCH WION LIVE HERE:

Scientists develop microrobots that surround a cancer cell and kill it

Scientists have found that the cancer-causing virus Epstein Barr Virus (EBV) can infect the neuronal cells and drive various changes in biomolecules such as fatty acids, carbohydrates, and protein components, leading to diseases of the central nervous system as well as brain cancer. EBV virus has been found to be widely present in the human population. It usually does not cause any harm, but the virus gets reactivated inside the body in some unusual conditions like immunological stress or immunocompetent, as reported by PIB.

This may further lead to various complications like a type of blood cancer called Burkitt’s lymphoma, stomach cancer, multiple sclerosis, and so on. Earlier studies provided links to EBV involvement in various neurodegenerative diseases. However, how this virus can affect the cells of the brain and manipulate them is still unexplored.&nbsp;

A research team from IIT Indore utilized the Raman microspectroscopy technique, supported by the Department of Science and Technology (DST) under the FIST scheme to explore the possible impacts of a cancer-causing virus on brain cells. The technique based on Raman Effect is a simple, cost-effective tool to find sensitive chemical changes in biological samples. The study, published in the journal ACS Chemical Neuroscience, showed that there could be timely and gradual changes in various biomolecules in the neuronal cells under the viral influence. Additionally, these changes were distinct when compared to the changes observed in other supportive brain cells (that is, astrocyte and microglia).

Also Read:<a href="https://www.wionews.com/science/canada-south-asian-communities-may-have-suffered-most-during-pandemic-says-study-495404">&nbsp;Canada: South Asian communities may have suffered most during pandemic, says study</a>

As reported by PIB, the team observed that the lipid, cholesterol, proline, and glucose molecules increased in the cells under the viral influence. These biomolecular entities could ultimately play pivotal roles in the viral usurpation of cells. Further, the study also provided insights into whether these biomolecular changes can be correlated to virus-associated impacts and linked to neurological complications. “The research work aids in the understanding of EBV-mediated biomolecular changes in the various compartments of the central nervous system leading to a better understanding of nervous system diseases,” said Dr Hem Chandra Jha.

Professor Rajesh Kumar pointed out that the study is also helpful in establishing the advantages of Raman microspectroscopy, a cost-effective and non-invasive technique, in carrying out studies on virus-associated cellular complications in clinical settings. It could provide an upper hand in analysing clinical samples in comparison to other techniques, which require advanced setups for studying the virus-associated changes in cells, tissues, and organs.

(with inputs from agencies)

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

Scientists have found that the cancer-causing virus Epstein Barr Virus (EBV) can infect the neuronal cells and drive various changes in biomolecules such as fatty acids, carbohydrates, and protein components, leading to diseases of the central nervous system as well as brain cancer.

Scientists have found that the cancer-causing virus Epstein Barr Virus (EBV) can infect the neuronal cells and drive various changes in biomolecules such as fatty acids, carbohydrates, and protein components, leading to diseases of the central nervous system as well as brain cancer. EBV virus has been found to be widely present in the human population. It usually does not cause any harm, but the virus gets reactivated inside the body in some unusual conditions like immunological stress or immunocompetent, as reported by PIB. This may further lead to various complications like a type of blood cancer called Burkitt’s lymphoma, stomach cancer, multiple sclerosis, and so on. Earlier studies provided links to EBV involvement in various neurodegenerative diseases. However, how this virus can affect the cells of the brain and manipulate them is still unexplored. A research team from IIT Indore utilized the Raman microspectroscopy technique, supported by the Department of Science and Technology (DST) under the FIST scheme to explore the possible impacts of a cancer-causing virus on brain cells. The technique based on Raman Effect is a simple, cost-effective tool to find sensitive chemical changes in biological samples. The study, published in the journal ACS Chemical Neuroscience, showed that there could be timely and gradual changes in various biomolecules in the neuronal cells under the viral influence. Additionally, these changes were distinct when compared to the changes observed in other supportive brain cells (that is, astrocyte and microglia). Also Read: Canada: South Asian communities may have suffered most during pandemic, says study As reported by PIB, the team observed that the lipid, cholesterol, proline, and glucose molecules increased in the cells under the viral influence. These biomolecular entities could ultimately play pivotal roles in the viral usurpation of cells. Further, the study also provided insights into whether these biomolecular changes can be correlated to virus-associated impacts and linked to neurological complications. “The research work aids in the understanding of EBV-mediated biomolecular changes in the various compartments of the central nervous system leading to a better understanding of nervous system diseases,” said Dr Hem Chandra Jha. Professor Rajesh Kumar pointed out that the study is also helpful in establishing the advantages of Raman microspectroscopy, a cost-effective and non-invasive technique, in carrying out studies on virus-associated cellular complications in clinical settings. It could provide an upper hand in analysing clinical samples in comparison to other techniques, which require advanced setups for studying the virus-associated changes in cells, tissues, and organs. (with inputs from agencies) WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

Study suggests this cancer-causing virus can lead to brain cancer

A CDC study has raised an alarm in the US after it was found that Glyphosate increases the risk of cancer. Around 80% of US urine samples contain Glyphosate.

Glyphosate increases risk of cancer; CDC study raises alarm in US

The science that was utilized to create the COVID-19 vaccine by AstraZeneca is currently being modified for use as a vaccination for cancer patients.

COVID-19 technology used to treat cancer patients

Technoblade, a well-known Minecraft YouTuber, <a href="https://www.wionews.com/entertainment/popular-youtuber-technoblade-dies-from-cancer-at-the-age-of-23-493659">died </a>at the age of 23 after a protracted fight with cancer that lasted almost a year. His parents produced a heart-touching video as a moving tribute that made the late Youtuber's followers mourn the loss. The final video on the YouTuber's channel featured his parting message, which his father read aloud.

Technoblade gained recognition by livestreaming and releasing videos of himself playing the sandbox video game, and now has over 10 million YouTube subscribers. The late YouTuber's parents issued a note to fans at the end of their video in which they admitted how devoted Technoblade was to his audience.

The final part of the video featured a statement from Technoblade's family.

"We, the family of Technoblade , wanted all of you to know just how much he adored and respected his fans and colleagues. From Technoblade’s earliest online days, he was always strategizing ways to delight and reward his audience—giving away online prizes, encouraging good sportsmanship, and most of all sharing his Minecraft adventures for entertainment and laughs. Even after his eventual successes, he somehow managed to keep his good – natured humility , competing with an endearing balance between confidence and self deprecating wit, "the statement read.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
Technoblade has passed away after his battle with cancer, his father delivered a final message on his behalf today. 
 
May he rest in peace. <a href="https://t.co/z2dL5xzjvB">pic.twitter.com/z2dL5xzjvB</a>
— Jake Lucky (@JakeSucky) <a href="https://twitter.com/JakeSucky/status/1542685440091623425?ref_src=twsrc%5Etfw">July 1, 2022</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

A homage to him may also be found on Technoblade's website, where it is stated that a part of sales will be given to the Sarcoma Foundation of America. "The family of Technoblade is in charge of this internet store. We want to make sure we keep spreading his message since we are aware of how much joy he has brought to others over the years "It is read.

There is currently a black T-shirt for sale in the shop that says, "so long geeks," "Alexander "Technoblade"," and "1999-2022" underneath.

More heartfelt condolences to Technoblade have been posted online by his friends and followers. Some have followed the YouTuber for years, while others are fellow producers and partners.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false"><iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="315" src="https://www.youtube.com/embed/DPMluEVUqS0" title="YouTube video player" width="560"></iframe></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

The online celebrity had revealed in a fundraising video released in February that he had undergone chemotherapy, radiation therapy, and a limb salvage operation after developing a painful tumour in his right arm. He won Minecraft tournaments and amassed hordes of fans by humorously talking about his life while playing the game. Sarcoma, a rare bone and soft tissue malignancy, caused his death. 
&nbsp;

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

Technoblade, a well-known Minecraft YouTuber, died at the age of 23 after a protracted fight with cancer that lasted almost a year. His parents produced a heart-touching video as a moving tribute that made the late Youtuber's followers mourn the loss.

Technoblade, a well-known Minecraft YouTuber, died at the age of 23 after a protracted fight with cancer that lasted almost a year. His parents produced a heart-touching video as a moving tribute that made the late Youtuber's followers mourn the loss. The final video on the YouTuber's channel featured his parting message, which his father read aloud. Technoblade gained recognition by livestreaming and releasing videos of himself playing the sandbox video game, and now has over 10 million YouTube subscribers. The late YouTuber's parents issued a note to fans at the end of their video in which they admitted how devoted Technoblade was to his audience. The final part of the video featured a statement from Technoblade's family. "We, the family of Technoblade , wanted all of you to know just how much he adored and respected his fans and colleagues. From Technoblade’s earliest online days, he was always strategizing ways to delight and reward his audience—giving away online prizes, encouraging good sportsmanship, and most of all sharing his Minecraft adventures for entertainment and laughs. Even after his eventual successes, he somehow managed to keep his good – natured humility , competing with an endearing balance between confidence and self deprecating wit, "the statement read. Technoblade has passed away after his battle with cancer, his father delivered a final message on his behalf today. May he rest in peace. pic.twitter.com/z2dL5xzjvB — Jake Lucky (@JakeSucky) July 1, 2022 × A homage to him may also be found on Technoblade's website, where it is stated that a part of sales will be given to the Sarcoma Foundation of America. "The family of Technoblade is in charge of this internet store. We want to make sure we keep spreading his message since we are aware of how much joy he has brought to others over the years "It is read. There is currently a black T-shirt for sale in the shop that says, "so long geeks," "Alexander "Technoblade"," and "1999-2022" underneath. More heartfelt condolences to Technoblade have been posted online by his friends and followers. Some have followed the YouTuber for years, while others are fellow producers and partners. × The online celebrity had revealed in a fundraising video released in February that he had undergone chemotherapy, radiation therapy, and a limb salvage operation after developing a painful tumour in his right arm. He won Minecraft tournaments and amassed hordes of fans by humorously talking about his life while playing the game. Sarcoma, a rare bone and soft tissue malignancy, caused his death. WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

Tributes pour in as YouTuber and Minecraft streamer Technoblade dies at 23

A new report by the European Environment Agency (EEA) has revealed that pollution is linked to more than 10 per cent of cancer cases in Europe.

2.7 million people are diagnosed with cancer each year in the European Union and 1.3 million die from it.&nbsp;

Europe reports almost a quarter of new cancer cases and a fifth of deaths even though it accounts for less than 10 per cent of the world's population.

The EEA said in its report that air pollution is linked to around one percent of all cancer cases in Europe, and causes around two percent of all cancer deaths.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/1-in-6-deaths-due-to-pollution-in-2019-modern-pollutants-spike-deaths-480215/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

The report, which is the agency's first on the link between cancer and the environment, highlights that "all environmental and occupational cancer risks can be reduced," according to EEA expert Gerardo Sanchez.

While UV radiation may be responsible for up to four percent of all cancer cases in Europe, indoor exposure to radon is linked to up to two percent of all cancer cases, and one in ten lung cancer cases in the continent.

Warning that some chemicals used in European workplaces contribute to causing cancer, the agency said exposure to second-hand smoke may increase the overall risk for all cancers by up to 16 percent for people who have never been smokers.

Asbestos, a well-known carcinogen, which was banned in 2005 by the EU, it is still present in some buildings and is estimated to account for 55 to 88 per cent of occupational lung cancers.&nbsp;

"Environmental and occupational cancer risks can be reduced by cleaning up pollution and changing behaviours," the agency said.&nbsp;

"Decreasing these risks will lead to a fall in the numbers of cancer cases and deaths," it added. 
&nbsp;

(With inputs from agencies)

Watch WION's live TV here:

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false"><iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1&lt;/div">&amp;times;</iframe></div>

&nbsp;
</div>

A new report by the European Environment Agency (EEA) has revealed that pollution is linked to more than 10 per cent of cancer cases in Europe. 2.7 million people are diagnosed with cancer each year in the European Union and 1.

A new report by the European Environment Agency (EEA) has revealed that pollution is linked to more than 10 per cent of cancer cases in Europe. 2.7 million people are diagnosed with cancer each year in the European Union and 1.3 million die from it. Europe reports almost a quarter of new cancer cases and a fifth of deaths even though it accounts for less than 10 per cent of the world's population. The EEA said in its report that air pollution is linked to around one percent of all cancer cases in Europe, and causes around two percent of all cancer deaths. × The report, which is the agency's first on the link between cancer and the environment, highlights that "all environmental and occupational cancer risks can be reduced," according to EEA expert Gerardo Sanchez. While UV radiation may be responsible for up to four percent of all cancer cases in Europe, indoor exposure to radon is linked to up to two percent of all cancer cases, and one in ten lung cancer cases in the continent. Warning that some chemicals used in European workplaces contribute to causing cancer, the agency said exposure to second-hand smoke may increase the overall risk for all cancers by up to 16 percent for people who have never been smokers. Asbestos, a well-known carcinogen, which was banned in 2005 by the EU, it is still present in some buildings and is estimated to account for 55 to 88 per cent of occupational lung cancers. "Environmental and occupational cancer risks can be reduced by cleaning up pollution and changing behaviours," the agency said. "Decreasing these risks will lead to a fall in the numbers of cancer cases and deaths," it added. (With inputs from agencies) Watch WION's live TV here:

New report reveals pollution linked to 10% of cancer cases in Europe

Jiratti Kuttanam, who is facing stage four breast cancer, finds solace in the glass jars of dried cannabis stashed in the cupboard.

Thai cancer patient welcomes Cannabis legislation

Watch an exclusive conversation with the Bollywood actress Sonali Bendre. She spoke about her cancer journey and her OTT debut. She is making a comeback with her latest 'The Broken News'.

WION Exclusive: Sonali Bendre speaks about her cancer journey and OTT debut

According to a study of more than five million people in the United States, it is discovered that the incidence of esophageal cancer in middle-aged adults nearly doubled from 2012 to 2019. Last month's peer-reviewed publication in EurekAlert stated that adults aged 45 to 64 in Florida experienced a nearly doubled rate of esophageal cancer and a 50 per cent increase in the precancerous condition Barrett's esophagus during the mentioned period. The database analysis is to be presented at Digestive Disease Week® 2022.&nbsp;

Esophageal cancer is a disease in which malignant cells form in the tissues of the oesophagus, which is a long and hollow tube that connects the throat to the stomach. It is basically a cancer of the oesophagus.&nbsp;

It is mostly&nbsp;caused by smoking, heavy alcohol use and Barrett's esophagus can increase the risk of esophageal cancer. Weight loss and painful or difficult swallowing are some of the symptoms of esophageal cancer.&nbsp;

As per reports, it is the sixth leading cause of mortality from cancer globally. Although, it majorly depends on the person's geographical factor as well. It is usually detected by endoscopy. However, signs are minimal until it becomes advanced - making it a silent killer.&nbsp;

Bashar J Qumseya, MD, MPH, FASGE, who is the lead author of the study, said, "This strong growth in prevalence should be of concern to physicians, and we should consider screening more middle-aged patients for esophageal cancer if they are at higher risk."&nbsp;

Qumseya is also the associate professor of medicine and chief of endoscopy at the University of Florida, Gainesville. "Whenever we see increasing prevalence of any type of cancer, we should ask whether this is merely due to better screening or it is a true increase in the disease prevalence. In our study, it was due to the latter," Qumseya added.&nbsp;

The study team assessed the rate of esophagogastroduodenoscopy (EGD) during this timeframe and found no increase. The study stated that the finding might explain the prevalence data.&nbsp;

As per the research, esophageal cancer and Barrett's esophagus are most common in older white men. Those who are over 65 have the greatest prevalence, the research tells.&nbsp;

The cancer incidence in the 45-to-64 age bracket about doubled, from 49 to 94 per 100,000, while the frequency of Barrett’s esophagus increased by roughly 50 per cent, from 304 to 466 per 100,000 individuals.&nbsp;

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

According to a study of more than five million people in the United States, it is discovered that the incidence of esophageal cancer in middle-aged adults nearly doubled from 2012 to 2019.

According to a study of more than five million people in the United States, it is discovered that the incidence of esophageal cancer in middle-aged adults nearly doubled from 2012 to 2019. Last month's peer-reviewed publication in EurekAlert stated that adults aged 45 to 64 in Florida experienced a nearly doubled rate of esophageal cancer and a 50 per cent increase in the precancerous condition Barrett's esophagus during the mentioned period. The database analysis is to be presented at Digestive Disease Week® 2022. Esophageal cancer is a disease in which malignant cells form in the tissues of the oesophagus, which is a long and hollow tube that connects the throat to the stomach. It is basically a cancer of the oesophagus. It is mostly caused by smoking, heavy alcohol use and Barrett's esophagus can increase the risk of esophageal cancer. Weight loss and painful or difficult swallowing are some of the symptoms of esophageal cancer. As per reports, it is the sixth leading cause of mortality from cancer globally. Although, it majorly depends on the person's geographical factor as well. It is usually detected by endoscopy. However, signs are minimal until it becomes advanced - making it a silent killer. Bashar J Qumseya, MD, MPH, FASGE, who is the lead author of the study, said, "This strong growth in prevalence should be of concern to physicians, and we should consider screening more middle-aged patients for esophageal cancer if they are at higher risk." Qumseya is also the associate professor of medicine and chief of endoscopy at the University of Florida, Gainesville. "Whenever we see increasing prevalence of any type of cancer, we should ask whether this is merely due to better screening or it is a true increase in the disease prevalence. In our study, it was due to the latter," Qumseya added. The study team assessed the rate of esophagogastroduodenoscopy (EGD) during this timeframe and found no increase. The study stated that the finding might explain the prevalence data. As per the research, esophageal cancer and Barrett's esophagus are most common in older white men. Those who are over 65 have the greatest prevalence, the research tells. The cancer incidence in the 45-to-64 age bracket about doubled, from 49 to 94 per 100,000, while the frequency of Barrett’s esophagus increased by roughly 50 per cent, from 304 to 466 per 100,000 individuals. WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

Researchers find alarming increase in a type of cancer in middle-aged adults

Three new studies show that losing a large amount of weight through weight-loss surgery can considerably reduce your chance of developing or dying from cancer. According to a study presented Tuesday at the American Society for Metabolic and Bariatric Surgery's (ASMBS) annual meeting in Dallas, obese people who had bariatric surgery were at least two times less likely to develop certain types of cancer and more than three times less likely to die of cancer than obese people who didn't have the procedure.

According to results published June 3 in the Journal of the American Medical Association, another much larger trial by the Cleveland Clinic revealed similar, if smaller, benefits from weight-loss surgery: a 32 percent lower risk of acquiring cancer and a 48 percent lower risk of cancer-related death.

Also read |&nbsp;<a href="https://www.wionews.com/entertainment/lifestyle/news-world-food-safety-day-2022-tips-to-ensure-food-safety-avoid-foodborne-risks-485859">World Food Safety Day 2022: Tips to ensure food safety, avoid foodborne risks</a>

<div class="ui-state-default" contenteditable="false">
<div class="row">
<div class="article-blockquote">
<div class="col-sm-10 col-sm-offset-1 blockquote-content quoteshare">
<blockquote>
<h5>Weight reduction has a dose-dependent association with cancer risk, according to the findings: the more weight you lose, the lower your cancer risk.Another study presented at the ASMBS summit on Tuesday discovered that bariatric surgery lowered the risk of colon cancer by 37%.</h5>
</blockquote>
</div>

<div class="col-sm-1 blockquote-content">
<div class="share-blockquote"><a class="twitter popup" href="http://twitter.com/intent/tweet?text=Weight reduction has a dose-dependent association with cancer risk, according to the findings: the more weight you lose, the lower your cancer risk.Another study presented at the ASMBS summit on Tuesday discovered that bariatric surgery lowered the risk of colon cancer by 37%." target="_blank">&nbsp;</a></div>
</div>
<a class="close-mark close-div" href="#" id="jqquoteclosemark">×</a></div>
</div>
</div>

To achieve this cancer protection, people must lose at least 20% of their body weight, which is well beyond the ability of those seeking to lose weight by diet and exercise, according to senior researcher Dr. Ali Aminian, director of the Cleveland Clinic's Bariatric and Metabolic Institute. 
 
<a href="https://www.wionews.com/science/a-lot-of-happy-tears-cancer-disappears-in-every-patient-in-a-small-drug-trial-485905">Also read | 'A lot of happy tears': Cancer 'disappears' in every patient in a small drug trial</a>

More than 42 percent of Americans are obese, according to the Centers for Disease Control and Prevention.Their extra weight raises their risk of acquiring 13 malignancies, which account for two out of every five cancers diagnosed in the United States each year.

Given the global obesity epidemic, obesity is predicted to overtake smoking as the leading cause of cancer in the near future, according to Aminian.

Watch | Gravitas: Medical miracle: Clinical trial manages to free 14 patients of cancer

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-medical-miracle-clinical-trial-manages-to-free-14-patients-of-cancer-486370/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

According to a report presented at the ASMBS meeting, the first study compared more than 2,100 bariatric surgery patients against more than 5,500 obese adults who qualified for the treatment but did not have it.

According to the researchers, breast cancer (1.4 percent vs. 2.7 percent), gynecologic cancer (0.4 percent vs. 2.6 percent), kidney cancer (0.10 percent vs. 0.80 percent), brain cancer (0.20 percent vs. 0.90 percent), lung cancer (0.20 percent vs. 0.60 percent), and thyroid cancer (0.10 percent vs. 0.70 percent) were all significantly reduced by weight-loss surgery.

The weight-loss surgery group also had a reduced incidence of any new malignancy (approximately 5.2 percent vs. slightly over 12 percent) and a greater survival rate over a decade (93 percent vs. 79 percent). 
&nbsp;

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

Three new studies show that losing a large amount of weight through weight-loss surgery can considerably reduce your chance of developing or dying from cancer. According to a study presented Tuesday at the American Society for Metabolic and Bariatric Surgery's (ASMBS) annual meeting in Dallas, obese people who had bariatric surgery were at least two times less likely to develop certain types of cancer and more than three times less likely to die of cancer than obese people who didn't have the procedure.

Three new studies show that losing a large amount of weight through weight-loss surgery can considerably reduce your chance of developing or dying from cancer. According to a study presented Tuesday at the American Society for Metabolic and Bariatric Surgery's (ASMBS) annual meeting in Dallas, obese people who had bariatric surgery were at least two times less likely to develop certain types of cancer and more than three times less likely to die of cancer than obese people who didn't have the procedure. According to results published June 3 in the Journal of the American Medical Association, another much larger trial by the Cleveland Clinic revealed similar, if smaller, benefits from weight-loss surgery: a 32 percent lower risk of acquiring cancer and a 48 percent lower risk of cancer-related death. Also read | World Food Safety Day 2022: Tips to ensure food safety, avoid foodborne risks Weight reduction has a dose-dependent association with cancer risk, according to the findings: the more weight you lose, the lower your cancer risk.Another study presented at the ASMBS summit on Tuesday discovered that bariatric surgery lowered the risk of colon cancer by 37%. × To achieve this cancer protection, people must lose at least 20% of their body weight, which is well beyond the ability of those seeking to lose weight by diet and exercise, according to senior researcher Dr. Ali Aminian, director of the Cleveland Clinic's Bariatric and Metabolic Institute. Also read | 'A lot of happy tears': Cancer 'disappears' in every patient in a small drug trial More than 42 percent of Americans are obese, according to the Centers for Disease Control and Prevention.Their extra weight raises their risk of acquiring 13 malignancies, which account for two out of every five cancers diagnosed in the United States each year. Given the global obesity epidemic, obesity is predicted to overtake smoking as the leading cause of cancer in the near future, according to Aminian. Watch | Gravitas: Medical miracle: Clinical trial manages to free 14 patients of cancer According to a report presented at the ASMBS meeting, the first study compared more than 2,100 bariatric surgery patients against more than 5,500 obese adults who qualified for the treatment but did not have it. According to the researchers, breast cancer (1.4 percent vs. 2.7 percent), gynecologic cancer (0.4 percent vs. 2.6 percent), kidney cancer (0.10 percent vs. 0.80 percent), brain cancer (0.20 percent vs. 0.90 percent), lung cancer (0.20 percent vs. 0.60 percent), and thyroid cancer (0.10 percent vs. 0.70 percent) were all significantly reduced by weight-loss surgery. The weight-loss surgery group also had a reduced incidence of any new malignancy (approximately 5.2 percent vs. slightly over 12 percent) and a greater survival rate over a decade (93 percent vs. 79 percent). WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

Weight-loss surgery cuts the risk of developing cancer by 37%

There has been a crucial breakthrough in the fight against the cancer. A trial was carried out at a cancer center in New York. Patients were injected with a drug, and after 6 months, cancer tumors vanished in all patients.

Medical Miracle: After 6 months, Cancer vanished in all patients

A human, who is apparently a medical trial participant, has been injected with a virus that is aimed at killing cancer cells in the body. The virus has shown positive results on animals. The treatment is called oncolytic virus therapy. As mentioned in the research and studies, oncolytic viruses are a form of immunotherapy that uses viruses to infect and destroy cancer cells. Experts have noted that the viruses infect or enter our cells and then use the cell's genetic machinery to replicate. The new "cancer-killing" virus, known as Vaxinia, has been designed to kill cancer cells and avoid healthy cells.&nbsp;

Newsweek report mentioned that for a period of approximately two years, the trial will aim to recruit 100 cancer patients across the United States.&nbsp;

As per Imugene Limited, which is a clinical cancer research company, the treatment can also help prime peoples' immune systems against cancer. Imugene Limited develops the virus Vaxinia, (full name CF33-hNIS VAXINIA). The company is specialised in novel therapies that activate the immune system against cancer.&nbsp;

In the news release published in EurekAlert On May 17, it is mentioned that the Imugene and City of Hope announce the "first patient dosed in Phase 1 trial to test cancer-killing oncolytic virus against solid tumours". Experts hope that the virus amplifies the body’s immune response against cancer.&nbsp;

The release added once patients in the single therapy group have been treated and "acceptable safety" has been demonstrated, new study participants will "receive the experimental oncolytic virus in combination with the immunotherapy pembrolizumab."&nbsp;

ALSO READ |&nbsp;<a href="https://www.wionews.com/science/no-evidence-found-over-mutation-in-monkeypox-virus-says-who-481635">No evidence found over mutation in monkeypox virus, says WHO's senior official</a>

WATCH |&nbsp;New York City Mayor declares emergency over nationwide baby formula shortage&nbsp;

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/us-new-york-city-mayor-declares-emergency-over-nationwide-baby-formula-shortage-481714/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

Daneng Li MD, the principal investigator and assistant professor of City of Hope's Department of Medical Oncology &amp; Therapeutics Research, said as quoted by the release: "Our previous research demonstrated that oncolytic viruses can stimulate the immune system to respond to and kill cancer, as well as stimulate the immune system to be more responsive to other immunotherapies, including checkpoint inhibitors."&nbsp;

"Now is the time to further enhance the power of immunotherapy, and we believe CF33-hNIS has the potential to improve outcomes for our patients in their battle with cancer," he added.&nbsp;

In phase 1 clinical trial, the virus will be injected into people who have solid tumours and have had at least two prior types of treatment. Reports added that the virus is either injected into the tumour directly or into a vein.&nbsp;

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

You can now write for wionews.com and be a part of the community. Share your stories and opinions with us <a href="https://www.wionews.com/content-contribution-registration-form">here</a>.

A human, who is apparently a medical trial participant, has been injected with a virus that is aimed at killing cancer cells in the body. The virus has shown positive results on animals.

A human, who is apparently a medical trial participant, has been injected with a virus that is aimed at killing cancer cells in the body. The virus has shown positive results on animals. The treatment is called oncolytic virus therapy. As mentioned in the research and studies, oncolytic viruses are a form of immunotherapy that uses viruses to infect and destroy cancer cells. Experts have noted that the viruses infect or enter our cells and then use the cell's genetic machinery to replicate. The new "cancer-killing" virus, known as Vaxinia, has been designed to kill cancer cells and avoid healthy cells. Newsweek report mentioned that for a period of approximately two years, the trial will aim to recruit 100 cancer patients across the United States. As per Imugene Limited, which is a clinical cancer research company, the treatment can also help prime peoples' immune systems against cancer. Imugene Limited develops the virus Vaxinia, (full name CF33-hNIS VAXINIA). The company is specialised in novel therapies that activate the immune system against cancer. In the news release published in EurekAlert On May 17, it is mentioned that the Imugene and City of Hope announce the "first patient dosed in Phase 1 trial to test cancer-killing oncolytic virus against solid tumours". Experts hope that the virus amplifies the body’s immune response against cancer. The release added once patients in the single therapy group have been treated and "acceptable safety" has been demonstrated, new study participants will "receive the experimental oncolytic virus in combination with the immunotherapy pembrolizumab." ALSO READ | No evidence found over mutation in monkeypox virus, says WHO's senior official WATCH | New York City Mayor declares emergency over nationwide baby formula shortage × Daneng Li MD, the principal investigator and assistant professor of City of Hope's Department of Medical Oncology & Therapeutics Research, said as quoted by the release: "Our previous research demonstrated that oncolytic viruses can stimulate the immune system to respond to and kill cancer, as well as stimulate the immune system to be more responsive to other immunotherapies, including checkpoint inhibitors." "Now is the time to further enhance the power of immunotherapy, and we believe CF33-hNIS has the potential to improve outcomes for our patients in their battle with cancer," he added. In phase 1 clinical trial, the virus will be injected into people who have solid tumours and have had at least two prior types of treatment. Reports added that the virus is either injected into the tumour directly or into a vein. WATCH WION LIVE HERE You can now write for wionews.com and be a part of the community. Share your stories and opinions with us here.

In a new clinical trial, first human patient injected with revolutionary cancer-killing virus

More than 42 million adults in the United States are projected to be either overweight or obese by the year 2040. The alarming report also raises concerns over cancer in the country as overweight and obese people are at a higher risk of 13 types of cancer

Over 20,000 cancer cases in UK attributed to obesity

Off White's chief executive officer and founder Virgil Abloh passed away at 41 after battling cancer for years. Virgil Abloh was one of the top US fashion designers, the artistic director of Louis Vuitton's menswear collection.

The barrier-breaking fashion designer Virgil Abloh dies of cancer at 41

Amidst reports of the Russian president Vladimir Putin's undergoing cancer treatment, ex-spy chief and a close aid of the Kremlin is expected to take control of the country and the ongoing Ukraine war.

Reports: Russian President Putin to undergo cancer treatment, handover power to ex-spy chief

cancer

Cancer, News on Cancer, stories on Cancer, articles on Cancer, Cancer stories at Wion, Cancer news, Cancer latest news